It is finally here!
We have been waiting to publish this report on the state of European biotech vs. US biotech which has been produced in cooperation with NovoFonden and ADC Consulting.
Report_-Bridging-the-Gap-–-Transforming-EU-Biotech-Policy.pdf
The outcome is concerning, however, not very surprising. The US takes a lead on almost every area, and most notably in terms of financing.
Som headlines from the report:
- Funding
There is a significant gap in available funding to biotech ventures across the development stages - Idea Translation
The EU’s focus on commercialization is relatively weak when contrasted with the US - Regulation
Both bureaucratic inefficiencies and regulation slow down approval times - Culture
Risk-adverse cultural attitudes slow down the pace and efficiency of the EU startup sector
The upsides then are:
- The talent pool exists in the EU
EU is actually in front when it comes to raising talent within biotech - There is a movement towards strategic autonomy
And with this, improved competitiveness - The start-up environments are improving
We have seen some great initiative, e.g. with BII as a good example in Denmark, to improve and lift the start-up environments
